Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 56 of the 58 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate glucose-dependent insulinotropic polypeptide (GIP) secretion in patients with type 2 diabetes and nondiabetic control subjects during oral glucose or meal tests. RESEARCH DESIGN AND METHODS: Eligible trials were identified by The Cochrane Library, MEDLINE, Embase, and Web of Science. Data were retrieved and random-effects models for the primary meta-analysis, random-effects meta-regression, and subgroup and regression analyses were applied. RESULTS: Random-effects meta-analysis of GIP responses in 23 trials during 28 different stimulation tests showed that patients with type 2 diabetes (n = 363) exhibited no significant differences (P = not significant) in peak plasma GIP, total area under the curve (tAUC), time-corrected tAUC (tAUC × min−1), and time-corrected incremental area under the curve (iAUC × min−1) in comparison with nondiabetic control subjects (n = 325) but had lower GIP responses as evaluated from iAUC (weighted mean difference, −648 pmol/L × min; 95% CI, −1,276 to −21). Fixed-effects models meta-analyses confirmed most of the results of the primary meta-analysis but showed iAUC × min−1 to be reduced and showed tAUC and tAUC × min−1 to be higher in diabetic patients. Random-effects meta-regression of the primary meta-analysis showed that age (peak GIP, tAUC, iAUC, and iAUC × min−1), BMI (tAUC, iAUC, and iAUC × min−1), and HbA1c (iAUC and iAUC × min−1) predicted some of the GIP outcomes. Post hoc subgroup analysis showed a negative influence of age and of HbA1c on GIP responses and showed a positive influence of BMI on GIP responses. CONCLUSIONS: Our results suggest that patients with type 2 diabetes are characterized by preserved GIP secretion in response to oral glucose and meal tests. They also suggest that high BMI is associated with increased GIP responses but increasing age and HbA1c are associated with reduced GIP secretion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Current research indicates that although GLP-1 secretion is preserved in individuals with T2DM, there is an impairment of GLP-1 function. This includes reduced ability to secrete insulin, heightened insulin resistance, and elevated blood sugar levels, potentially resulting in diminished expression of GLP-1 receptors and developing GLP-1 resistance.10”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Self-citationNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Self-citationLaferrère, B., Heshka, S., Wang, K., Khan, Y., McGinty, J., Teixeira, J., Hart, A. B., & Olivan, B. (2007) · Diabetes Care · doi:10.2337/dc06-1549 · Cited by 532
Self-citationVilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Self-citationNauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 1×
“Many factors previously have been positively associated with GIP responses, including BMI (34,45), female sex (28), and metformin treatment (22).”
BackgroundSelf-citationDeacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401
Self-citation
Research works printed but not linked: 1
- Nasteska, 2012, Lowering GIP secretion has beneficial role in reducing obesity and insulin resistance without impairing glucose tolerance and osteogenesis, Diabetologia, 55, S80
Cited by
Items 101–165 of 165
Suh, S., Kim, M. Y., Kim, S. K., Hur, K. Y., Park, M. K., Kim, D. K., Cho, N. H., & Lee, M. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.1.134 · Cited by 11
Enteroendocrine cell differentiation: Implications for human disease
Saint‐Denis, E., Frintu, B., Goldsmith, M., Ramos, G. P., & Zeve, D. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112607 · Cited by 12
Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes
Ahn, C. H., Oh, T. J., Min, S. H., & Cho, Y. M. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.103 · Cited by 10
Erfanian, S., Mir, H., Abdoli, A., & Roustazadeh, A. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01477-z · Cited by 10
Characterization of sporadic somatotropinomas with high GIP receptor expression
Faria, O., Miranda, R. L., Lima, C. H. D. A., Guterres, A., Ventura, N., Barbosa, M. Á., Camacho, A. H. D. S., Lamback, E. B., Andreiuolo, F. D. M., Chimelli, L. M. C., et al. (2022) · Pituitary · doi:10.1007/s11102-022-01272-6 · Cited by 9
Oteng, A., Liu, L., Cui, Y., Gavrilova, O., Lü, H., Chen, M., Weinstein, L. S., Campbell, J. E., Lewis, J. E., Gribble, F. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci182325 · Cited by 8
The Potential Mechanism of Remission in Type 2 Diabetes Mellitus After Vertical Sleeve Gastrectomy
Wang, R., Mijiti, S., Xu, Q., Liu, Y., Deng, C., Huang, J., Yasheng, A., Tian, Y., Cao, Y., & Su, Y. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07378-z · Cited by 9
Pal, B., & Chattopadhyay, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_117_23 · Cited by 8
Hoffmann, C., Schwarz, P. E. H., Mantzoros, C. S., Birkenfeld, A. L., Wolfrum, C., Solimena, M., Bornstein, S. R., & Perakakis, N. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110636 · Cited by 7
In Vivo Models for Incretin Research: From the Intestine to the Whole Body
Oh, T. J. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.1.45 · Cited by 8
Mohri, K., Misu, H., Takayama, H., Ishii, K., Kikuchi, A., Lan, F., Enyama, Y., Takeshita, Y., Saito, Y., Kaneko, S., et al. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00549 · Cited by 8
Incretin system and glucagon secretion in patients with chronic pancreatitis
Ciccarelli, G., Giuseppe, G. D., Gliozzo, G., Soldovieri, L., Quero, G., Nista, E. C., Brunetti, M., Cinti, F., Lucia, S. S. D., Hartmann, B., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70093 · Cited by 6
Self-citationRole of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
Trivedi, K., & Dolinsky, V. W. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0163 · Cited by 7
Oh, T. J., Park, K. S., & Cho, Y. M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12623 · Cited by 6
Insights into the structure and activation mechanism of some class B1 GPCR family members
Aksu, H., Demirbilek, A., & Uba, A. İ. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09876-w · Cited by 6
Plasminogen Activator Inhibitor‐1 in the Pathophysiology of Late Life Depression
Métivier, L., Vivien, D., Goy, R., Agin, V., Bui, É., & Benbrika, S. (2024) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.70015 · Cited by 6
Hasegawa, T., 駒形美穂, Hamasaki, A., Harada, N., Seino, Y., & Inagaki, N. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12896 · Cited by 7
Drewa, J., Lazar-Juszczak, K., Adamowicz, J., & Juszczak, K. (2025) · Cancers · doi:10.3390/cancers17091576 · Cited by 7
Gut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review
Tzeravini, E., Simati, S., Anastasiou, I. A., Dalamaga, Μ., & Kokkinos, A. D. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00687-7 · Cited by 8
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect
Mathiesen, D. S., Bagger, J. I., Hansen, K. B., Junker, A. E., Plamboeck, A., Østoft, S. H., Idorn, T., Hornum, M., Holst, J. J., Jonsson, A. E., et al. (2020) · Endocrine Connections · doi:10.1530/ec-20-0471 · Cited by 5
Self-citationSosibo, A. M., Mzimela, N. C., Ngubane, P. S., & Khathi, A. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01363-z · Cited by 5
Incretin secretion in obese Korean children and adolescents with newly diagnosed type 2 diabetes
Park, S. H., Jung, M. H., Cho, W. K., Park, M. S., & Suh, B. (2015) · Clinical Endocrinology · doi:10.1111/cen.12802 · Cited by 5
Gut hormones and Type 2 diabetes mellitus
Falinska, A. M., Tan, T., & Bloom, S. R. (2014) · Diabetes Management · doi:10.2217/dmt.14.47 · Cited by 4
Shibuki, K., Shimada, S., & Aoyama, T. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102474 · Cited by 4
Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
Wibawa, I. D. N., Mariadi, I. K., Somayana, G., Kumbara, C. I. Y. K., & Sindhughosa, D. A. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.549 · Cited by 4
Hamasaki, A., Harada, N., Muraoka, A., Yamane, S., Joo, E., Suzuki, K., & Inagaki, N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1301352 · Cited by 3
Hormones and Gastrointestinal Function of Newborns
Prodam, F., Bellone, S., Ricotti, R., Monzani, A., Genoni, G., Giglione, E., & Bona, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-18159-2_184-1 · Cited by 3
Altered GIP/GLP-1 Secretion Ratio is Associated With Impaired β Cell Function in Humans
Giuseppe, G. D., Gliozzo, G., Ciccarelli, G., Carciero, L., Brunetti, M., Soldovieri, L., Quero, G., Cinti, F., Nista, E. C., Lucia, S. S. D., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf210 · Cited by 3
Self-citationVaccines for metabolic diseases: current perspectives
Monteiro, M. P., Morais, T., Andrade, S., & Pereira, S. S. (2014) · Vaccine Development and Therapy · doi:10.2147/vdt.s47623 · Cited by 3
Targeting postprandial glycaemia in children with diabetes: O pportunities and challenges
Geyer, M. C., Rayner, C. K., Horowitz, M., & Couper, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13141 · Cited by 5
Identification of plasma binding proteins for glucose-dependent insulinotropic polypeptide
Hoshiyama, A., Fujimoto, K., Konno, R., Sasaki, S., Momozono, A., Kodera, Y., & Shichiri, M. (2019) · Endocrine Journal · doi:10.1507/endocrj.ej18-0472 · Cited by 3
Effects of incretin drugs on glycemic control and body weight
Levitskaya, A. N., Demidova, T. Y., & Геннадьевна, Л. К. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-3-07 · Cited by 2
The molecular mechanisms of incretin resistance in Type 2 Diabetes Mellitus (T2DM)
Albaghlany, R. M., & Mansour, A. A. (2026) · Nutrition and Diabetes · doi:10.1038/s41387-026-00426-w · Cited by 2
Dobrzycka, M., & Karczewska‐Kupczewska, M. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02185-1 · Cited by 3
Yanagimachi, T., Fujita, Y., Takeda, Y., Honjo, J., Yokoyama, H., & Haneda, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00214 · Cited by 2
GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
Nauck, M. A., Blüher, M., Meyhöfer, S. M., Heitmann, E., & Görgens, S. W. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-2436 · Cited by 3
Mattos, A. M. D. S., Costa, S. C., Outuki, G., Koga, G. K. C., Montemor, C. N., Longo, G. Z., Watanabe, M. A. E., Amarante, M. K., & Mazzuco, T. L. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/340539 · Cited by 2
Pharmacological Interventions of Metabolic Syndrome
Mehta, A. A., Beladiya, J., & Gandhi, T. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-75686-3_22 · Cited by 2
Comparator clinical trials of surrogate endpoints with albiglutide are in HARMONY
Doggrell, S. A. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.995629 · Cited by 1
Effect of Bariatric Surgery on Incretin Function
Laferrère, B. (2015) · Springer eBooks · doi:10.1007/978-1-4939-3220-7_9 · Cited by 1
Self-citationEffects of glucose-dependent insulinotropic polypeptide on glucagon
Christensen, M., & Knop, F. K. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000093 · Cited by 1
Self-citationFactors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus
Yoo, S., Yang, E.-J., & Koh, G. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0105 · Cited by 2
Incretins Enhance PGF2α-Induced Synthesis of IL-6 and Osteoprotegerin in Osteoblasts
Hioki, T., Kuroyanagi, G., Fujita, K., Sakai, G., Kawabata, T., Kim, W. Y., Tachi, J., Matsushima‐Nishiwaki, R., Iida, H., Kozawa, O., et al. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1713-7967 · Cited by 1
Khiar, H., Lévêque, É., Lopez, A.-G., Moreau‐Grangé, L., Richard, L. M., Brunel, V., Perdrix, A., Takhlidjt, S., Devère, M., Tavolacci, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15871 · Cited by 1
Regulation of glucose metabolism by incretins: implications for treatment of type 2 diabetes
Saito, R., & Harada, N. (2024) · Diabetology International · doi:10.1007/s13340-024-00781-y · Cited by 2
Patel, K. A., Kettunen, J. L. T., Laakso, M., Stančáková, A., Laver, T. W., Colclough, K., Johnson, M. B., Abramowicz, M., Groop, L., Miettinen, P. J., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/101881 · Cited by 1
Pharmacometric Models of Glucose Homeostasis in Healthy Subjects and Diabetes Patients
Røge, R. M. (2016) · DiVA (Digitala Vetenskapliga Arkivet)
Utilising the therapeutic potential of xenin and related molecules for diabetes and obesity
Craig, S. L. (2020) · Ulster University Research Portal (Ulster University)
Incretin‐Based Therapy for the Management of Type 2 Diabetes
Gonzales, K., & Vella, A. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch12
Personalised medicine for Non-Alcoholic Fatty Liver Disease
Taylor, A. (2021) · Discovery Research Portal (University of Dundee)
Waris, N., Bano, S., Fawwad, A., & Basit, A. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-01028-1
Hormones and Gastrointestinal Function of Newborns
Prodam, F., Bellone, S., Ricotti, R., Monzani, A., Genoni, G., Giglione, E., & Bona, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-29489-6_184
Veränderungen der Sekretion und biologischen Wirksamkeit von Inkretinhormonen bei Typ-2-Diabetes
Quast, D. R., & Nauck, M. A. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01146-w
Régulation et fonctions du facteur de transcription ChREBP dans l'épithélium intestinal
Charifi, W. (2021) · theses.fr (ABES) · doi:10.70675/89543c3fz31abz4d56zaa7bz77c2c07ffd69
Incretins in healthy and type 2 diabetic people
Goglia, U. (2024) · The Journal of AMD · doi:10.36171/jamd24.27.2.3
Brown and white adipose tissue metabolism in obesity: stimulation by cold and meal ingestion
Saari, T. (2022) · UTUPub (University of Turku)
Pathogenesis of type 2 diabetes
Honka, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00376-9
インスリン療法で血糖コントロールが不十分な成人2型糖尿病患者に対するインクレチン関連薬追加療法の臨床試験間の異質性の解析とその応用
克也, 澁., & 澁木, 克. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.20604/00003779
Sun, Y., Xie, C., Bound, M. J., Jones, K. L., Horowitz, M., Macdonald, I. A., Young, R. L., Rayner, C. K., & Wu, T. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113235
Verma, S., Dasgupta, R., Shajith Anoop, S., Jebasingh, F. K., Chowdury, S. D., Jose, A., Varghese, G., Christudoss, P., Venkatesan, P., Rebekah, G. J., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-55406-y
Vignera, S. L., Fioriglio, C., & Condorelli, R. A. (2026) · Diagnostics · doi:10.3390/diagnostics16131979
Sinha, L., Sonia, D., & Gupta, D. R. (2025) · NeuroQuantology · doi:10.48047/nq.2025.23.7.nq25042
GLP-1 Receptor Agonists and Gout: A Narrative Review
Flint, C., Merriman, T. R., & Solomon, D. H. (2026) · Gout Urate and Crystal Deposition Disease · doi:10.3390/gucdd4040020
Metadata
- Authors
- Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K.
- Affiliations
- University of Copenhagen (DK)
- St. Luke's-Roosevelt Hospital Center (US)
- Corresponding author
- Knop, Filip K.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-09-14
- Volume
- 36
- Issue
- 10
- Pages
- 3346-3352
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3781498
- OpenAlex
- W2079429014
- Cited by
- 158
- References
- 58
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 17 · 2023: 11 · 2022: 13 · 2021: 10 · 2020: 13 · 2019: 13 · 2018: 14 · 2017: 17 · 2016: 11 · 2015: 11 · 2014: 12 · 2013: 1
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Novo Nordisk Fonden (NNF12OC1015904)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK026687)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucose-dependent insulinotropic polypeptide, GIP secretion, type 2 diabetes, oral glucose tolerance test, test meal, incretin response, body mass index, age, HbA1c, insulin secretion
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose Tolerance Test, Humans, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.